GlassScriptPhysician profile
Rema Dicen
NPI 1316545353
$2,979.16
in general payments reported to CMS, 2019-2025
26 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,972 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.92 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $527.88 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $501.21 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $282.00 | 2024-2025 | |
| Glaxosmithkline, LLC. | $252.48 | 2024-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $218.67 | 2024 | |
| Lilly USA, LLC | $154.61 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.25 | 2024-2025 | Jardiance |
| Bausch Health US, LLC | $115.02 | 2024-2025 | Wellbutrin, Aplenzin |
| Amgen INC. | $106.81 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $93.40 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $72.84 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.42 | 2024 | Xifaxan, Cycloset |
| Janssen Pharmaceuticals, INC | $55.47 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $50.54 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $50.47 | 2024-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $44.83 | 2025 | |
| Lundbeck LLC | $41.97 | 2024 | Rexulti |
| Pfizer INC. | $37.13 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $36.48 | 2024 | Rexulti |
| Bard Peripheral Vascular, INC. | $33.33 | 2025 | Lifestream |
| Esperion Therapeutics, INC. | $30.69 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $22.59 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $22.10 | 2024 | Inspire |
| Becton, Dickinson and Company | $19.20 | 2024 | |
| Biogen, INC. | $16.04 | 2024 | Leqembi |
| Sumitomo Pharma America, INC. | $14.73 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rema Dicen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.